Details of the Drug Pharmacogenomic Perturbation Atlas

Nicorandil Drug Info

Adancor; Dancor; Ikorel; Nicorandilum; Sigmart; Aventis Brand of Nicorandil; Aventis Pharma Brand of Nicorandil; Merck Brand of Nicorandil; Merck Lipha Sante Brand of Nicorandil; Nicorandil Aventis Brand; Nicorandil Merck Brand; Rhone Poulenc Rorer Brand of Nicorandil; SG 75; SG75; Ikorel (TN); Nicorandilum [INN-Latin]; RP-46417; Rhone-Poulenc Rorer Brand of Nicorandil; SG-75; Sigmart (TN); Nitrate, 2-Nicotinamidethyl; Nitrate, 2-Nicotinamidoethyl; N-(2-Hydroxyethyl)nicotinamide nitrate; Nicorandil (JP15/USAN/INN); Nicorandil [USAN:BAN:INN:JAN]; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; 2 Nicotinamidethyl Nitrate; 2 Nicotinamidoethyl Nitrate; 2-(Nicotinamido)ethyl nitrat; 2-(Pyridine-3-carboxamido)ethyl Nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; 2-Nicotinamidethyl Nitrate; 2-Nicotinamidoethyl nitrate; 2-[(pyridin-3-ylcarbonyl)amino]ethylnitrat

Therapeutic Class

Vasodilator Agents

Cross-matching ID

PubChem CID

47528

ChEBI ID

CHEMBL284906

CAS Number

CAS 65141-46-0

TTD Drug ID

D0O2SR

VARIDT Drug ID

DR01017

General Information of Drug (ID: DMIYJFV)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome	2.09	1.19e-2	113/158 (71.52%)	RPS4Y1;RPL36AL;MRPS2;...
Nicotinate and nicotinamide metabolism	-1.65	4.66e-2	25/35 (71.43%)	SIRT3;NAMPT;NADSYN1;...
Riboflavin metabolism	-1.65	4.92e-2	7/8 (87.5%)	ACP5;ACP1;BLVRB;...
D-Glutamine and D-glutamate metabolism	-1.65	5.00e-2	5/5 (100%)	GLS2;DGLUCY;GLUD2;...
Fat digestion and absorption	-1.69	3.09e-2	35/43 (81.4%)	APOA4;GOT2;PLPP1;...
Vitamin digestion and absorption	-1.71	2.70e-2	17/24 (70.83%)	LMBRD1;ABCC1;SLC19A2;...
Steroid hormone biosynthesis	-1.73	2.38e-2	43/61 (70.49%)	SULT2B1;UGT2B4;CYP11A1;...
Pertussis	-1.75	1.79e-2	64/76 (84.21%)	TLR4;LY96;CASP3;...
Arginine biosynthesis	-1.81	7.03e-3	17/22 (77.27%)	GLS2;GLUD2;ARG1;...
Fatty acid elongation	-1.82	6.88e-3	19/27 (70.37%)	HADH;ELOVL6;ELOVL1;...
Proteasome	-1.84	7.64e-3	44/46 (95.65%)	PSMC1;PSMB1;PSMC6;...
Retinol metabolism	-1.88	4.30e-3	41/68 (60.29%)	CYP2C9;ADH1C;UGT2B4;...
Biosynthesis of unsaturated fatty acids	-1.90	4.91e-3	21/27 (77.78%)	ELOVL6;ELOVL1;SCP2;...
Tryptophan metabolism	-1.91	2.87e-3	35/42 (83.33%)	ALDH3A2;CAT;ALDH7A1;...
Steroid biosynthesis	-1.98	0.00e+0	19/20 (95%)	EBP;MSMO1;SOAT1;...
Valine, leucine and isoleucine degradation	-2.08	0.00e+0	42/48 (87.5%)	MCCC2;ALDH6A1;ACAD8;...
PPAR signaling pathway	-2.08	0.00e+0	66/74 (89.19%)	ANGPTL4;LPL;SCD5;...
Pantothenate and CoA biosynthesis	-2.13	0.00e+0	14/21 (66.67%)	ALDH3A2;PPCDC;PANK2;...
Complement and coagulation cascades	-2.32	0.00e+0	76/85 (89.41%)	C9;F2R;FGA;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	15uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H